Medical School - MGR Medical University

Internship - Mercy Catholic Medical Center

Residency - Mercy Catholic Medical Center and National Health Service

Fellowship - West Virginia University

BOARD CERTIFICATIONS

Medical Oncology
Hematology

LANGUAGES
English, Tamil, Telugu

ACADEMIC HONORS & PROFESSIONAL ACHIEVEMENTS

Masters in Clinical Research, MGH Institute of Health Professions, Boston

BIOGRAPHY

Dr. Nagaiah received his medical degree from MGR Medical University in India and has been in practice for more than 20 years. His residency and internship were completed at Mercy Catholic Medical Center in Pennsylvania, and he completed a fellowship at West Virginia University. He earned a Masters in Clinical Research from the MGH Institute of Health Professions in Boston. Dr. Nagaiah has expertise in treating lymphoma, lung cancer, and breast cancer, among other conditions.

PHILOSOPHY

I believe that being an oncologist is a privilege that is not to be taken lightly. I strive to provide evidence-based care that is appropriate to my patients’ particular problem, recognizing and respecting individual patient’s wishes. I take a multidisciplinary approach to care, including alternative therapies that have been shown to be effective.

RESEARCH PUBLICATIONS

1. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid cancer: A review of epidemiology, pathogenesis, and treatment. J Oncol. 2011;2011:542358.
2. Batalo M, Nagaiah G, Abraham J. Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors. Expert Rev Anticancer Ther. 2011;11(8):1277-1282.
3. Nagaiah G, Remick SC. Combretastatin A4 phosphate: A novel vascular disrupting agent. Future Oncol. 2010;6(8):1219-1228
4. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 2009;19(3):233-240.
5. Nagaiah G, Almubarak M, Khan M, Altaha R. Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: Report of two cases and review of literature. Cancer Invest. 2010;28(10):1048-1053